RLAY icon

RLAY

Lightning icon

13.91 USD

+2.21%

Today

+3.36%

1D

Market is open

Sun

Closed

Mon

4:30 PM ~ 11:00 PM

Tue

4:30 PM ~ 11:00 PM

Wed

4:30 PM ~ 11:00 PM

Thu

4:30 PM ~ 11:00 PM

Fri

4:30 PM ~ 11:00 PM

Sat

Closed

Loading chart...
1D
5D
1M
3M
1Y
MAX

Information

Name

Relay Therapeutics Inc Leveraged

Currency

USD

Standard Leverage

1X

Lightning Icon

Enhanced Leverage

3X

Lightning Icon

Overnight Fees Buy

-0.0183%

Overnight Fees Sell

0.0016%

Market Cap

2.31B

Avg Daily Volume

4.30M

52 Week High

17.32 USD

52 Week Low

2.75 USD

Trading Hours

See hours

Overnight Fees Calculator

ExposureUnits
USD
Daily Overnight Fee %Daily Overnight Fee $
BUYS-0.01830%$(0.183)
SELLS0.00160%$0.016

*Results displayed are estimates. Actual fees may differ from those shown as market conditions change.

Business Summary

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Top News

Relay Therapeutics Announces Pricing of Public Offering of Common Stock

tradingview.com

5d ago

No Image

Relay Therapeutics Announces Proposed Public Offering of Common Stock

tradingview.com

6d ago

No Image

RLAY: Zovegalisib shows promising efficacy and safety in PIK3CA-driven vascular anomalies, supporting further trials

tradingview.com

1w ago

No Image

Show more

Frequently Asked Questions

What are healthcare stocks and why are they important to investors?

Healthcare stocks include pharmaceutical companies, biotech firms, hospitals, and medical device manufacturers.


Are healthcare stocks less volatile?

Generally yes. Because healthcare is a necessity, demand remains relatively steady, making the sector less sensitive to economic cycles.


What drives growth in healthcare investments?

Aging populations, technological advancements, and increased healthcare spending contribute to long-term growth in the sector.


What are the risks of investing in healthcare?

Regulatory changes, drug approval delays, and legal challenges can affect the profitability and stock prices of healthcare companies.